Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study

Anti-Cancer Drugs

Volumn 18, Issue 4, 2007, Pages 487-491

  Lin, Chia Chi ^a,b   Hsu, Chih Hung ^a,b   Huang, Chao Yuan ^a   Keng, Hsiao Yi ^a,b   Tsai, Yu Chieh ^a,b   Huang, Kuo How ^a   Cheng, Ann Lii ^a,b   Pu, Yeong Shiau ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antineoplastic agents; Bladder neoplasms; Deoxycytidine; Salvage; Transitional cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; MESNA; METHOTREXATE; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; VINBLASTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT TUMOR; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; DRUG RESISTANCE; HEMATOLOGIC DISEASE; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SURVIVAL; UROTHELIUM;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; MALE; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 34247593884     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280126603     Document Type: Article

References (28)

1. Bamias A, Tiliakos I, Karali MD, Dimopoulos MA. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol 2006; 17:553-561.
2. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006; 6:409-431.
3. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5:182-184.
4. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15:3441-3445.
5. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of singleagent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15:3394-3398.
6. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34:1208-1212.
7. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997; 15:589-593.
8. Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer 2006; 106:1269-1275.
9. Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS. Phase II trial of weekly paclitaxel, cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (TP-HDFL) for metastatic urothelial carcinoma. J Urol 2007; 177:84-89.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
12. Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 2001; 21:711-715.
13. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997; 75:606-607.
14. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20:937-940.
15. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15:1853-1857.
16. Winquist E, Vokes E, Moore MJ, Schumm LP, Hoving K, Stadler WM. A phase II study of oxaliplatin in urothelial cancer. Urol Oncol 2005; 23:150-154.
17. Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005; 23:143-149.
18. Machiels JP, Wulfing C, Richel DJ, Beuzeboc P, Garcia Del Muro X, Grimm MO, et al. A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis. J Clin Oncol 2004; 22:4615.
19. Sridhar SS, Stadler W, Le L, Hedley D, Pond G, Wright J, et al. Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. J Clin Oncol 2005; 23:4677.
20. Theodore C, Geoffrois L, Vermorken JB, Caponigro F, Fiedler W, Chollet P, et al. Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor and gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005; 41:1150-1157.
21. Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D'Armiento M, Bianco AR, et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol 2004; 34:747-750.
22. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, et al. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 2005; 104:1627-1632.
23. Sweeney CJ, Williams SD, Finch DE, Bihrle R, Foster RS, Collins M, et al. A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999; 86:514-518.
24. Krege S, Rembrink V, Borgermann C, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 2001; 165:67-71.
25. Pectasides D, Aravantinos G, Kalofonos H, Kiamouris C, Bafaloukos D, Xiros N, et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2001; 12:1417-1422.
26. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006; 24:3451-3457.
27. Culine S, Theodore C, De SM, Bui B, Demkow T, Lorenz J, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94:1395-1401.
28. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107:506-513.